Plasma levels of soluble platelet glycoprotein V are linked to fasting blood glucose in patients with type 2 diabetes

Boris Aleil; Laurence Kessler; Nicolas Meyer; Marie-Louise Wiesel; Julia Simeoni; Jean-Pierre Cazenave; Michel Pinget; Christian Gachet; François Lanza

doi:10.1160/TH08-04-0244

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(04): 713-715
DOI: 10.1160/TH08-04-0244

Letters to the Editor

Schattauer GmbH

Plasma levels of soluble platelet glycoprotein V are linked to fasting blood glucose in patients with type 2 diabetes

Boris Aleil

¹EFS-Alsace, Strasbourg, France

²INSERM, U311, Strasbourg, France

,

Laurence Kessler

³Service d'Endocrinologie, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

,

Nicolas Meyer

⁴Département de Santé Publique, Unité de Méthodologie et Biostatistique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

,

Marie-Louise Wiesel

¹EFS-Alsace, Strasbourg, France

,

Julia Simeoni

³Service d'Endocrinologie, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

,

Jean-Pierre Cazenave

¹EFS-Alsace, Strasbourg, France

²INSERM, U311, Strasbourg, France

,

Michel Pinget

³Service d'Endocrinologie, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

,

Christian Gachet

¹EFS-Alsace, Strasbourg, France

²INSERM, U311, Strasbourg, France

,

François Lanza

¹EFS-Alsace, Strasbourg, France

²INSERM, U311, Strasbourg, France

› Author Affiliations

Abstract

Full Text

References

References
1 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-2581.
2 Creager MA, Luscher TF, Cosentino F. et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-1532.
3 Yamada T, Sato A, Nishimori T. et al. Importance of hypercoagulability over hyperglycaemia for vascular complication in type 2 diabetes. Diabetes Res Clin Pract 2000; 49: 23-31.
4 Aoki I, Shimoyama K, Aoki N. et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol 1996; 27: 560-566.
5 Bern MM. Platelet functions in diabetes mellitus. Diabetes 1978; 27: 342-50.
6 Ferroni P, Basili S, Falco A. et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 02: 1282-1291.
7 Azorsa DO, Moog S, Ravanat C. et al. Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA--its use to follow platelet storage in transfusion. Thromb Haemost 1999; 81: 131-138.
8 Phillips DR, Agin PP. Platelet plasma membrane glycoproteins. Identification of a proteolytic substrate for thrombin. Biochem Biophys Res Commun 1977; 75: 940-947.
9 Blann AD, Lanza F, Galajda P. et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking. Thromb Haemost 2001; 86: 777-783.
10 Kamath S, Blann AD, Chin BS, et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J 2002; 23: 1788-1795.
11 Wolff V, Aleil B, Giroud M. et al. Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke 2005; 36: e17-e19.
12 Aleil B, Mossard JM, Wiesel ML. et al. Increased plasma levels of soluble platelet glycoprotein V in patients with acute myocardial infarction. J Thromb Haemost 2003; 01: 1846-1847.
13 Morel O, Hugel B, Jesel L. et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost 2004; 91: 345-353.
14 Huisse MG, Lanoy E, Tcheche D. et al. Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. Thromb Haemost 2007; 98: 420-426.
15 Aleil B, Meyer N, Wolff V. et al. Plasma glycoproteinV levels in the general population: normal distribution, associated parameters and implications for clinical studies. Thromb Haemost 2006; 96: 505-511.
16 Hornbuckle J, Vail A, Abrams KR. et al. Bayesian interpretation of trials: the example of intrapartum electronic fetal heart rate monitoring. Br J Obstet Gynecol 2000; 107: 3-10.
17 Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J R Stat Soc Ser A Stat Soc 1994; 157: 357-416.
18 Hoeting JA, Madigan D, Raftery AE. et al. Bayesian Model Averaging: A Tutorial. Statistical Science 1999; 14: 382-417.
19 Rabie T, Strehl A, Ludwig A. et al. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoproteinV. J Biol Chem 2005; 280: 14462-14468.
20 Alison KD, Elizabeth JE, Kristine CYM. et al. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263-269.